Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias

Watanabe, Kizuku; Handa, Tomohiro; Tanizawa, Kiminobu; Hosono, Yuji; Terada, Yoshio; Noma, Satoshi; Kobashi, Yoichiro; Kubo, Takeshi; Aihara, Kensaku; Chin, Kazuo; Nagai, Sonoko; Mimori, Tsuneyo; Mishima, Michiaki

doi:10.1016/j.rmed.2011.03.022

Cited by 108 publications

(115 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, antibodies useful for diagnosing CTD showed their primary autoantigen sources in the lung, such as Jo-1 and anti-citrullinated protein antibody (ACPA) [29][30][31]. In some other cases, antibodies are associated with prevalent lung involvement, such as ATSA and anti-Th/To [32,33], and in IPF autoantibodies are less rare [34,35].…”

Section: Discussionmentioning

confidence: 99%

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances

Sambataro

Sambataro²,

Torrisi

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

@ERSpublications IPAF retrospective cohorts show numerous differences between them. We propose some ideas to improve IPAF criteria http://ow.ly/eubC30jlGJO ABSTRACT The term interstitial pneumonia with autoimmune features (IPAF) has been proposed to define patients with interstitial lung disease (ILD) associated with autoimmune signs not classifiable for connective tissue diseases (CTDs). This new definition overcomes previous nomenclatures and provides a uniform structure for prospective studies through specific classification criteria.This work evaluates the characteristics of IPAF patients reported in the literature, to highlight potential limits through a comparative analysis and to suggest better performing classification criteria.Four retrospective studies on the IPAF population have been considered. The study subjects differed in age, sex, smoking habit, ILD pattern and outcomes. Another important difference lies in the diverse items considered in the classification criteria. The retrospective design of the studies and the absence from some of them of a rheumatologist clearly involved in the diagnosis may have influenced the data, but current IPAF criteria seem to include a rather heterogeneous population. To overcome these discrepancies, this review suggests a limitation in the use of single items and the exclusion of extremely specific CTD criteria. This should avoid the definition of IPAF for those diseases at different stages or at early onset. The investigation of a functional or morphological cut-off of pulmonary involvement would be useful.

show abstract

Section: Discussionmentioning

confidence: 99%

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances

Sambataro

Sambataro²,

Torrisi

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…20 Indeed, anti-ARS antibodies can be detected in about 5-10% of unselected IIP patients. 35,36 High resolution computed tomography (HRCT) findings of anti-ARS-positive patients with ILD show predominant involvement of the lower lung fields and the peripheral and/or the peribronchovascular region. Ground-glass opacity (GGO), intralobular reticular opacity, traction bronchiectasis and lower lobe volume loss are frequently observed.…”

Section: Anti-ars Antibodiesmentioning

confidence: 99%

Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

Nakashima

Hosono

Mimori

2016

Lupus

View full text Add to dashboard Cite

Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 ( MDA5) antibodies are closely associated with interstitial lung disease in polymyositis and dermatomyositis. Anti-ARS-positive patients develop common clinical characteristics termed anti-synthetase syndrome and share a common clinical course, in which they respond well to initial treatment with glucocorticoids but in which disease tends to recur when glucocorticoids are tapered. Anti- MDA5 antibody is associated with rapidly progressive interstitial lung disease and poor prognosis, particularly in Asia. Therefore, intensive immunosuppressive therapy is required for anti- MDA5-positive patients from the early phase of the disease. New enzyme-linked immunosorbent assays to detect anti-ARS and anti- MDA5 antibodies have recently been established and are suggested to be efficient and useful. These assays are expected to be widely applied in daily practice.

show abstract

“…anti-ARS antibodies screening, 7% of patients with idiopathic interstitial pneumonia were positive for anti-ARS antibodies 8) . These facts suggest that a certain number of antisynthetase syndrome patients present ILD alone or with atypical skin changes at the beginning and might be treated as patients with idiopathic interstitial pneumonia.…”

Section: Case Reportmentioning

confidence: 99%

Anti-EJ antibody positive interstitial lung disease with skin changes at the fingertips

Kihara

Takamura

et al. 2016

Jpn. J. Clin. Immunol.

View full text Add to dashboard Cite

Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias

Abstract: Anti-synthetase positive cases were not rare among IIPs. Anti-synthetase should be screened for in IIPs, especially in pathological NSIP or UIP with lymphoid follicles. These patients should be screened for anti-synthetase even if no suggestive extrapulmonary manifestation exists.

Cited by 108 publications

References 36 publications

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances

Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

Anti-EJ antibody positive interstitial lung disease with skin changes at the fingertips

Contact Info

Product

Resources

About